Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539

NEXT STORY
Continued ICP Orders From Japanese Customers
PREV STORY
Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TESARO Summarizes TSR-042 Clinical Data Presented at AACR

author_avatar
NASDAQ Market News

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

author_avatar
NASDAQ Market News

Global Respiratory Syncytial Virus Markets, 2017-2020 & 2021-2027 – Increasing Disease Burden / Advent of Targeted Therapies / High Cost of Disease Management

author_avatar
NASDAQ Market News